Search Within

Neha Sanat Korde

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (49)
  2. Journal Article (12)
  3. Research Letter (4)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (66)
  2. Department of Medicine (66)
  3. Hematologic Malignancies, Division of (66)
  4. Myeloma (66)
  5. Population Sciences Research Program (66)
  6. Survivorship Research (66)

More Groups

People
  1. Alexander Lesokhin (65)
  2. Hani Hassoun (65)
  3. Malin Hultcrantz (65)
  4. Sham Mailankody (65)
  5. Urvi Shah (64)
  6. Andriy Derkach (63)

More People

Years
  1. 2025 (1)
  2. 2024 (13)
  3. 2023 (17)
  4. 2022 (19)
  5. 2021 (9)
  6. 2020 (6)

More Years

Publications
  1. Blood (24)
  2. Clinical Lymphoma, Myeloma and Leukemia (19)
  3. Journal of Clinical Oncology (6)
  4. Blood Cancer Journal (4)
  5. American Journal of Hematology (2)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Elsevier Inc. (20)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (5)
  5. American Association for Cancer Research (2)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (66)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Continuous mobile wearable bio-monitoring of newly diagnosed multiple myeloma patients undergoing initial chemotherapy
    Meeting Abstract

    Tavitian, E.; Mastey, D.; Salcedo, M.; Zarski, A.; Chansakul, A.; Diab, V.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; more...
    Blood (2018)

    Fulltext@MSK | Save